COMMUNIQUÉS West-GlobeNewswire

Une famille soutient la recherche sur les cancers rares par l’intermédiaire de la Fondation du CUSM
16/06/2026
MONTRÉAL, 16 juin 2026 (GLOBE NEWSWIRE) -- La générosité d’une famille permet de réaliser une percée majeure dans la recherche sur les cancers rares au CUSM. Dans le cadre du Projet SDR de la Fondation du CUSM, Jim [...]
ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of CSTI-500 for Prader-Willi Syndrome
16/06/2026
RENSSELAER, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. (“ConSynance”), a clinical-stage biotechnology company developing first-in-class therapies for neurobehavioral symptoms in rare [...]
Sanuwave Health Updates Second Quarter 2026 Guidance
16/06/2026
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE [...]
Pycnogenol® Brings a “Less-is-More” Approach to the Women’s Health Stack
16/06/2026
Clinically studied French maritime pine bark extract supports skin, circulation, menopause wellness and mobility in one multifunctional ingredient GENEVA, June 16, 2026 (GLOBE NEWSWIRE) -- From hydration and collagen [...]
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
16/06/2026
Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026 ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard [...]
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
16/06/2026
The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics Proprietary CELZ-Biodefense Toxic Exposure Atlas [...]
Klow Peptide Stack Introduced by Koi Peptides for Laboratory Research in 2026
16/06/2026
Sheridan, WY, June 16, 2026 (GLOBE NEWSWIRE) -- Koi Peptides (Koi Research Labs LLC) has introduced Klow Peptide Stack as a research-use-only multi-peptide blend for laboratory research in 2026. The product contains GHK [...]
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
16/06/2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, [...]
Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
16/06/2026
Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by mid-July 2026, with [...]
WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026
16/06/2026
Auckland, New Zealand, June 16, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, today announced that it will effect a [...]
CDT Equity Announces Debt Update and New Loan Facility
16/06/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has re-structured its debt, agreeing to pay off all [...]
Wolverine Peptide Stack & Blend Introduced by Koi Peptides for Laboratory Research
16/06/2026
Sheridan, WY, June 16, 2026 (GLOBE NEWSWIRE) -- Koi Peptides (Koi Research Labs LLC) has introduced Wolverine Peptide Stack as a research-use-only peptide stack for laboratory research. The product combines BPC-157 and [...]
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
16/06/2026
Intellectual property update confirms pelareorep’s unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional patent filings [...]
Erdem Hospital Highlights Emotional Wellbeing as Part of Patient Care with London Wellness Event
16/06/2026
The free London gathering reflects Erdem Hospital’s belief that recovery is more than physical, with guided breathing, gentle movement, and human connection playing an important role in the patient’s journey ISTANBUL, [...]
Through the MUHC Foundation, one family helps fuel breakthrough in rare cancer research
16/06/2026
MONTREAL, June 16, 2026 (GLOBE NEWSWIRE) -- One family’s generosity is helping drive a major breakthrough in rare cancer research at the MUHC. Through the MUHC Foundation’s SDR Project, Jim Hindley, his granddaughter [...]
Le King Faisal Specialist Hospital présente la chirurgie robotique comme modèle de soins spécialisés axés sur l’innovation lors du congrès HLTH Europe 2026
16/06/2026
AMSTERDAM, 16 juin 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) met en avant son leadership en chirurgie robotique à l’occasion de sa participation au congrès HLTH Europe 2026 [...]
Sharecare selected by Georgia Department of Community Health to advance rural health transformation through GREAT Health Program
16/06/2026
Company’s next-generation digital health experience, AskMD, to help Georgians better understand health risks, improve outcomes, and foster long-term well-being ATLANTA, June 16, 2026 (GLOBE NEWSWIRE) -- Sharecare, the [...]
MultiValent Biotherapies Launches with $27 Million Series A Financing to Advance Development of Targeted Prostate Cancer Drug Conjugate
16/06/2026
- First closing of $27 million Series A financing - - Funding will support Phase 1b/2a clinical trial of MVB-101, a prostate-specific membrane antigen x folate receptor alpha (PSMA x FRα) targeted drug conjugate - - [...]
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
16/06/2026
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which [...]

Pages